Neuphoria Therapeutics (NEUP) Current Assets (2021 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Current Assets of $21.7 million for Q1 2026, up 26.73% year-over-year from $17.1 million in Q1 2025, and down 7.39% quarter-over-quarter from $23.4 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Current Assets (2021 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Current Assets for 6 consecutive years, with $21.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 26.73% year-over-year to $21.7 million; the TTM figure through Mar 2026 stood at $21.7 million (up 26.73% YoY), while the FY2025 annual figure was $15.0 million, up 14.0% from the prior year.
- Current Assets eased to $21.7 million in Q1 2026 per NEUP's latest filing, from $23.4 million in the prior quarter.
- Across five years, Current Assets topped out at $29.9 million in Q2 2022 and bottomed at $4.4 million in Q4 2024.
- Historically, Current Assets has averaged $16.1 million across 5 years, with a median of $14.5 million in 2025.
- Annual changes were most pronounced in 2023 — Current Assets sank 55.15% — and 2025, when it jumped 431.69%.
- Neuphoria Therapeutics' Current Assets stood at $29.9 million in 2022, then tumbled by 55.15% to $13.4 million in 2023, then tumbled by 67.25% to $4.4 million in 2024, then surged by 431.69% to $23.4 million in 2025, then fell by 7.39% to $21.7 million in 2026.
- Business Quant data shows NEUP's Current Assets at $21.7 million in Q1 2026, $23.4 million in Q4 2025, and $14.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 21.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.66 Mn |
| Dec 31, 2025 | 23.39 Mn |
| Sep 30, 2025 | 13.95 Mn |
| Jun 30, 2025 | 15.04 Mn |
| Mar 31, 2025 | 17.09 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Sep 30, 2024 | 8.43 Mn |
| Jun 30, 2024 | 13.19 Mn |
| Jun 30, 2023 | 13.43 Mn |
| Jun 30, 2022 | 29.95 Mn |
| Jun 30, 2021 | 23.82 Mn |